Fexofenadine use was associated with a significant decline in MCP-1, 8-OHdG, and PCX compared to baseline values.<h4>Conclusion</h4>Fexofenadine is a possible promising adjuvant therapy in patients with DKD. This evidence concerns the gene CCL2 and diabetic kidney disease.